Analyst Activity – Raymond James Financial, Inc. Initiates Coverage On Antares Pharma (NASDAQ:ATRS) With a Strong-Buy

28

Analyst Ratings For Antares Pharma (NASDAQ:ATRS)

Today, Raymond James Financial, Inc. initiated coverage on Antares Pharma (NASDAQ:ATRS) with a Strong-Buy with a price target of $4.30.

There are 2 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Antares Pharma (NASDAQ:ATRS) is Buy (Score: 3.33) with a consensus target price of $3.10 per share, a potential 12.32% upside.

Some recent analyst ratings include

  • 4/20/2017-Raymond James Financial, Inc. initiated coverage with a Strong-Buy rating.
  • 8/13/2016-Piper Jaffray Companies Reiterated Rating of Overweight.
  • 5/10/2016-Jefferies Group LLC Reiterated Rating of Buy.
  • 9/25/2015-Oppenheimer Holdings Inc. Reiterated Rating of Buy.

Dividend information for Antares Pharma (NASDAQ:ATRS)

.
Recent Insider Trading Activity For Antares Pharma (NASDAQ:ATRS)
Antares Pharma (NASDAQ:ATRS) has insider ownership of 10.77% and institutional ownership of 33.60%.

  • On 4/5/2017 Robert F Apple, CEO, sold 40,000 with an average share price of $3.00 per share and the total transaction amounting to $120,000.00. View SEC Filing
  • On 4/4/2017 Leonard S Jacob, Director, sold 41,762 with an average share price of $2.89 per share and the total transaction amounting to $120,692.18. View SEC Filing
  • On 4/4/2017 Robert F Apple, CEO, sold 37,000 with an average share price of $3.00 per share and the total transaction amounting to $111,000.00. View SEC Filing
  • On 4/3/2017 Leonard S Jacob, Director, sold 20,000 with an average share price of $2.88 per share and the total transaction amounting to $57,600.00. View SEC Filing
  • On 3/31/2017 Thomas J Garrity, Director, sold 30,000 with an average share price of $2.91 per share and the total transaction amounting to $87,300.00. View SEC Filing
  • On 12/9/2016 Fred M Powell, Insider, bought 100,000 with an average share price of $2.03 per share and the total transaction amounting to $203,000.00. View SEC Filing
  • On 3/21/2016 Peter J Graham, SVP, bought 20,000 with an average share price of $0.77 per share and the total transaction amounting to $15,400.00. View SEC Filing

About Antares Pharma (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Recent Trading Activity for Antares Pharma (NASDAQ:ATRS)
Shares of Antares Pharma closed the previous trading session at 2.76 up +0.04 1.47% with 1,153,406 shares trading hands.

An ad to help with our costs